bioRxivPhysiology
Metabolic dysregulation of the lysophospholipid/autotaxin axis in the chromosome 9p21 gene SNP rs10757274
S. Meckelmann, J. Hawksworth, D. White, R. Andrews, P. Rodrigues, A. O'Connor, J. Alvarez Jarreta, V. Tyrrell, C. Hinz, Y. Zhou, J. Williams, M. Aldrovandi, W. J. Watkins, A. Engler, D. Slatter, S. Allen, J. Acharya, J. Mitchell, J. Cooper, J. Aoki, K. Kano, S. Humphries, V. B. O'Donnell
Abstract
AimsCommon chromosome 9p21 SNPs increase coronary heart disease (CHD) risk, independent of \"traditional lipid risk factors\". However, lipids comprise large numbers of structurally-related molecules not measured in traditional risk measurements, and many have inflammatory bioactivities. Here we applied lipidomic and genomic approaches to three model systems, to characterize lipid metabolic changes in common Chr9p21 SNPs which confer [~]30% elevated CHD risk associated with altered expression of ANRIL, a long ncRNA.\n\nMethods and ResultsUntargeted and targeted lipidomics was applied to plasma samples from Northwick Park Heart Study II (NPHSII) homozygotes for AA or GG in rs10757274. Elevated risk GG correlated with reduced lysophosphospholipids (lysoPLs), lysophosphatidic acids (lysoPA) and autotaxin (ATX). Five other risk SNPs did not show this phenotype. Correlation and network analysis showed that lysoPL-lysoPA interconversion was uncoupled from ATX in GG, indicating metabolic dysregulation. To identify candidate genes, transcriptomic data from shRNA downregulation of ANRIL in HEK293 cells was mined. Significantly-altered expression of several lysoPL/lysoPA metabolising enzymes was found (MBOAT2, PLA2G4C, LPCAT2, ACSL6, PNPLA2, PLBD1, PLPP1, PLPP2 and PLPPR2). Next, vascular smooth muscle cells differentiated from iPSCs of individuals homozygous for Chr9p21 risk SNPs were examined. Here, the presence of risk alleles was associated with altered expression of several lysoPL/lysoPA enzymes. Importantly, for several, deletion of the risk locus fully or partially reversed their expression to non-risk haplotype levels: ACSL3, DGKA, PLA2G2A, LPCAT2, LPL, PLA2G3, PNPLA3, PLA2G12A LIPC, LCAT, PLA2G6, ACSL1, MBOAT2.\n\nConclusionA Chr9p21 risk SNP associates with complex alterations in immune-bioactive phospholipids and their enzymatic metabolism. Lipid metabolites and genomic pathways associated with CHD pathogenesis in Chr9p21 and ANRIL-associated disease are demonstrated.\n\nOne sentence summaryInflammatory phospholipid metabolism defines a cardiovascular disease SNP
- organism: human
- assay: bulk RNA-seq
- assay: metabolomics
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: statistical model
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Variant-Specific Rewiring of Lysosomal Positioning by STARD9 Produces Opposite Cholesterol Trafficking Outcomes
Mehdi Dianatpour, Dipanjan Banerjee, … Arya Mani·bioRxiv·Sep 26, 2026
- Polygenic Hyperlipidemias and Coronary Artery Disease Risk
Pietari Ripatti, Joel T Rämö, … Samuli Ripatti·AtherosclerosisPeer-reviewed·Aug 1, 2017
- Genome-wide analysis of blood lipid metabolites in over 5,000 South Asians reveals biological insights at cardiometabolic disease loci
Eric L. Harshfield, Eric B. Fauman, … Albert Koulman·BMC MedicinePeer-reviewed·Sep 9, 2021
- Implicating genes, pleiotropy and sexual dimorphism at blood lipid loci through multi-ancestry meta-analysis
Stavroula Kanoni, Sarah E. Graham, … Pala Mauro·Genome biologyPeer-reviewed·Dec 27, 2022
- Metabolomic signatures of lipid-modifying therapies using drug target Mendelian randomization
Tom G. Richardson, Genevieve M Leyden, … Michael Vaclav Holmes·PLoS BiologyPeer-reviewed·Feb 25, 2022
- Genetics of human plasma lipidome: Understanding lipid metabolism and its link to diseases beyond traditional lipids
Rubina Tabassum, Joel T Rämö, … Samuli Ripatti·bioRxiv·Oct 31, 2018